Capital Counsel’s Bio-Techne TECH Stock Holding History

Capital Counsel’s Portfolio TECH Stock Details TECH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.22M	Hold	73,850	–	–	0.2%	21
2026 Q1	$3.86M	Hold	73,850	–	–	0.16%	20
2025 Q4	$4.34M	Sell	73,850 -150	-0.2%	-$9.11K	0.17%	21
2025 Q3	$4.12M	Buy	+74,000	New	+$3.96M	0.16%	21

Other funds holding TECH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Capital Counsel's TECH Position: Q2 2026 in Review

Capital Counsel held its Bio-Techne (TECH) position steady in Q2 2026 at 73,850 shares worth $5.22M. The position accounts for 0.2% of the portfolio, ranked #21.

Capital Counsel first reported a position in TECH in Q3 2025 and has held it in 4 quarters since. 596 funds tracked by Wall St. Rank hold TECH as of Q2 2026.

Capital Counsel held 73,850 shares of Bio-Techne worth $5.22M as of Q2 2026.
Capital Counsel left its Bio-Techne share count unchanged in Q2 2026.
Bio-Techne made up 0.2% of Capital Counsel's portfolio in Q2 2026, its #21 holding.
Capital Counsel first reported a position in Bio-Techne in Q3 2025 and has held it in 4 quarters since.
596 funds tracked by Wall St. Rank held Bio-Techne as of Q2 2026.

Based on Capital Counsel's 13F filing for Q2 2026, filed 12 Aug 2026.